Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
2.686
Zitationen
29
Autoren
2010
Jahr
Abstract
Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)
Ähnliche Arbeiten
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
2012 · 6.471 Zit.
Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop
2005 · 4.274 Zit.
Nomenclature of Systemic Vasculitides
1994 · 3.841 Zit.
Criteria for diagnosis of Behçet's disease
1990 · 3.080 Zit.
The Banff 97 working classification of renal allograft pathology
1999 · 3.045 Zit.
Autoren
- John H. Stone
- Peter A. Merkel
- Robert Spiera
- Philip Seo
- Carol A. Langford
- Gary S. Hoffman
- Cees G. M. Kallenberg
- E. William St. Clair
- Anthony Turkiewicz
- Nadia K. Tchao
- Lisa Webber
- Linna Ding
- Lourdes P. Sejismundo
- Kathleen Mieras
- David Weitzenkamp
- David Iklé
- Vicki Seyfert‐Margolis
- Mark Mueller
- Paul Brunetta
- Nancy B. Allen
- Fernando C. Fervenza
- Duvuru Geetha
- Karina A. Keogh
- Eugene Y. Kissin
- Paul A. Monach
- Tobias Peikert
- Coen A. Stegeman
- Steven R. Ytterberg
- Ulrich Specks
Institutionen
- Massachusetts General Hospital(US)
- Boston Medical Center(US)
- Boston University(US)
- University Medical Center(US)
- Hospital for Special Surgery(US)
- Johns Hopkins University(US)
- Cleveland Clinic(US)
- University of Groningen(NL)
- Duke University(US)
- University of Alabama at Birmingham(US)
- Immune Tolerance Network(US)
- National Institute of Allergy and Infectious Diseases(US)
- Mayo Clinic(US)
- United States Food and Drug Administration(US)